SIGMA HEALTHCARE LIMITED (SIG)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SIG

SIG - SIGMA HEALTHCARE LIMITED

FNArena Sector : Health & Nutrition
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -3.13
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$2.86

07 Aug
2025

-0.030

OPEN

$2.87

-1.04%

HIGH

$2.90

12,297,565

LOW

$2.85

TARGET
$2.82 -1.4% downside
Franking for last dividend paid out: 50%
OTHER COMPANIES IN THE SAME SECTOR
CLV . EBO . EXL . MCP .
FNARENA'S MARKET CONSENSUS FORECASTS
SIG: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx 0.4 4.5 xxx
DPS (cps) xxx 1.0 1.5 xxx
EPS Growth xxx 100.0% 100.0% xxx
DPS Growth xxx 1.5% 54.3% xxx
PE Ratio xxx N/A 63.1 xxx
Dividend Yield xxx N/A 0.5% xxx
Div Pay Ratio(%) xxx 223.9% 33.5% xxx

Dividend yield today if purchased 3 years ago: 1.43%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.34

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 28/03 - ex-div 0.5c (franking 50%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-0.9
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx4,841.2 M
Book Value Per Share xxxxxxxxxxxxxxx53.2
Net Operating Cash Flow xxxxxxxxxxxxxxx-315.6 M
Net Profit Margin xxxxxxxxxxxxxxx-0.29 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-1.62 %
Return on Invested Capital xxxxxxxxxxxxxxx-1.41 %
Return on Assets xxxxxxxxxxxxxxx-0.85 %
Return on Equity xxxxxxxxxxxxxxx-1.62 %
Return on Total Capital xxxxxxxxxxxxxxx-5.79 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-339.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx11 M
Long Term Debt xxxxxxxxxxxxxxx121 M
Total Debt xxxxxxxxxxxxxxx132 M
Goodwill - Gross xxxxxxxxxxxxxxx89 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx15 M
Price To Book Value xxxxxxxxxxxxxxx5.39

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx7.9 M
Capex % of Sales xxxxxxxxxxxxxxx0.16 %
Cost of Goods Sold xxxxxxxxxxxxxxx4,586 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx313 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx9 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

-0.1

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

5

xxxxxxxxxx xx xxxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

2

xxxxxxx xx xxxxxxxxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

22/07/2025

5

Underperform

$2.60

-9.09%

Macquarie highlights a lack of confidence in 2025 continues to be an overhang on consumer spending, but share prices for consumer-related stocks have run ahead of the recovery expected as the RBA lowers interest rates.

Coles Group ((COL)) is a key pick for the broker, together with Harvey Norman ((HVN)) and Bega Cheese ((BGA)).

Sigma Healthcare remains an avoid, with Endeavour Group ((EDV)), as Macquarie believes the market is discounting too much growth for the combined entity, although earnings growth should still be "sector leading".

Target price is lowered to $2.60 from $2.70. Lower growth in advertising results in a reduction in the analyst's forecast EPS by -7% for FY25 and -6% for FY26.

FORECAST
Macquarie forecasts a full year FY25 dividend of 1.50 cents and EPS of 4.60 cents.
Macquarie forecasts a full year FY26 dividend of 4.10 cents and EPS of 6.40 cents.

Morgans

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

24/07/2025

2

Overweight

$3.30

15.38%

Jarden flags Sigma Healthcare is aiming to lift the store size for Chemist Warehouse, with many of the older stores now space constrained and smaller at under 400sqm.

The analyst expects Sigma will increase the store size, which will lower sales per sqm but result in higher average store sales, which is a net positive. Chemist Warehouse currently generates around $13.9m sales per store and sales per sqm of around $26k, on Jarden's estimates.

Assuming around 20%-25% of the network is overtrading (smaller stores), the analyst believes net sales can grow at over 50% of incremental space uplift, with over 7% group sales as a potential tailwind in the next five years.

No change to Overweight rating and $3.30 target. The broker's EPS estimates remain unchanged.

FORECAST
Jarden forecasts a full year FY25 dividend of 0.00 cents and EPS of 5.00 cents.
Jarden forecasts a full year FY26 dividend of 3.60 cents and EPS of 5.90 cents.
Access Extra Coverage Research History >

SIG STOCK CHART

FNArena News on SIG

1
Rudi’s View: AI Updates, Hot Favourites & First August Results

Aug 07 2025 - Rudi's View
2
Rudi’s View: Consumer Stocks, Insurers, Telcos & More

Jul 31 2025 - Rudi's View
3
Weekly Ratings, Targets, Forecast Changes – 25-07-25

Jul 28 2025 - Weekly Reports
4
Rudi’s View: Bega Cheese, Cettire, Harvey Norman, Sigma, SiteMinder & More

Jul 24 2025 - Rudi's View
5
Australian Broker Call *Extra* Edition – Jul 24, 2025

Jul 24 2025 - Daily Market Reports

Latest Health & Nutrition News

1
Sigma Healthcare: Synergies, Margins In Focus

Jun 19 2025 - Australia
2
Sigma Healthcare Promises Higher Margins

Oct 03 2023 - Small Caps
3
Sigma’s Win Not Neccessarily Ebos’ Loss

Jun 14 2023 - Small Caps
4
Sigma Healthcare: Brokers Wary

Mar 31 2022 - Australia
5
Health & Wellness Boom On The ASX

Apr 29 2021 - Weekly Reports
6
M&A Now On Sigma Healthcare’s Agenda

Mar 24 2021 - Australia
7
McPherson’s Expands Into Herbal Health

Nov 04 2020 - Small Caps
8
Nine Ignored Companies Now Worth A Look

Sep 23 2020 - FYI
9
Next Week At A Glance – 14-18 Sep 2020

Sep 11 2020 - Weekly Reports
10
Sigma Farewells API, Heralds New Contract

Dec 17 2019 - Australia